Catch up on the 9 FDA drug approvals most relevant to primary care, including new options for HIV-1 infection, narcolepsy, diabetes, pain management, and more.
News|Slideshows|July 11, 2025
9 Drugs Approved for Primary Care: Q2 2025
Author(s)Sydney Jennings
Fact checked by: Grace Halsey
These new FDA-approved drugs include treatments for migraine, chronic spontaneous urticaria, RSV, and more.
Advertisement
Advertisement
As another quarter rounds out, a new batch of drugs have been approved by the US FDA for conditions often seen in primary care. Above, find details on the first dihydroergotamine nasal powder product to be approved for the acute treatment of migraine in adults, the first targeted therapy approved for chronic spontaneous urticaria (CSU) in more than a decade, and 7 more.
Related to this article
FDA updates sotatercept-csrk label with HYPERION data, showing earlier use cuts PAH clinical worsening risk 76% alongside background therapy.
The CardioGuide HF app from Abbott will show patients their pulmonary artery pressure trends and deliver medication instructions set by their care teams.
TMS 2026: OB/GYN visits had nearly 4-fold higher odds of menopause coding than family medicine visits, with disparities by race and insurance, a study found.
JoAnn Pinkerton, MD, discusses new research she presented at The Menopause Society 2026 Annual Meeting on elinzanetant for menopausal vasomotor symptoms.
TMS 2026: Women exercising at least 5 days a week reported lower perimenopause symptom scores across psychological, somatic, and urogenital domains.
TMS 2026: Menopause hormone therapy was associated with greater weight loss on semaglutide, but not sustained additional benefits with tirzepatide, in a new study.
Hormone Therapy Linked to More Frequent Migraines, but Not Greater Severity, in Postmenopausal Women
TMS 2026: A meta-analysis of 5 studies found hormone therapy linked to more frequent migraine attacks and migraine days, but not greater severity or analgesic use.
Advertisement
Advertisement